title: Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
abstract: The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytometry in MM-PCs from 230 MM patients at diagnosis included in the Grupo Español de Mieloma (GEM)05>65 years trial as well as 56 high-risk smoldering MM (SMM). CD81 expression was detected in 45% (103/230) MM patients, and the detection of CD81(+) MM-PC was an independent prognostic factor for progression-free (hazard ratio=1.9; P=0.003) and overall survival (hazard ratio=2.0; P=0.02); this adverse impact was validated in an additional series of 325 transplant-candidate MM patients included in the GEM05 <65 years trial. Moreover, CD81(+) SMM (n=34/56, 57%) patients had a shorter time to progression to MM (P=0.02). Overall, our results show that CD81 may have a relevant role in MM pathogenesis and represent a novel adverse prognostic marker in myeloma.
authors.affiliation: Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Paiva
authors.forename: N-C
authors.initials: NC
authors.lastname: Gutiérrez
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: M-B
authors.initials: MB
authors.lastname: Vídriales
authors.forename: M-Á
authors.initials: MÁ
authors.lastname: Montalbán
authors.forename: L
authors.initials: L
authors.lastname: Rosiñol
authors.forename: A
authors.initials: A
authors.lastname: Oriol
authors.forename: J
authors.initials: J
authors.lastname: Martínez-López
authors.forename: M-V
authors.initials: MV
authors.lastname: Mateos
authors.forename: L
authors.initials: L
authors.lastname: López-Corral
authors.forename: E
authors.initials: E
authors.lastname: Díaz-Rodríguez
authors.forename: J-J
authors.initials: JJ
authors.lastname: Pérez
authors.forename: E
authors.initials: E
authors.lastname: Fernández-Redondo
authors.forename: F
authors.initials: F
authors.lastname: de Arriba
authors.forename: L
authors.initials: L
authors.lastname: Palomera
authors.forename: E
authors.initials: E
authors.lastname: Bengoechea
authors.forename: M-J
authors.initials: MJ
authors.lastname: Terol
authors.forename: R
authors.initials: R
authors.lastname: de Paz
authors.forename: A
authors.initials: A
authors.lastname: Martin
authors.forename: J
authors.initials: J
authors.lastname: Hernández
authors.forename: A
authors.initials: A
authors.lastname: Orfao
authors.forename: J-J
authors.initials: JJ
authors.lastname: Lahuerta
authors.forename: J
authors.initials: J
authors.lastname: Bladé
authors.forename: A
authors.initials: A
authors.lastname: Pandiella
authors.forename: J-F San
authors.initials: JF
authors.lastname: Miguel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality; D010950:Plasma Cells / Q000378:metabolism*; D011379:Prognosis; D016019:Survival Analysis; D060225:Tetraspanin 28 / Q000235:genetics* / Q000378:metabolism
chemical_list: D060225:Tetraspanin 28